Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 10,357 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Fanconi Anemia
Interventions: Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil; Biological · Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 59 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Basal Cell Nevus Syndrome, Gorlin Syndrome
Interventions: GDC-0449; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 35 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Oakland, California • New York, New York

Conditions: Sickle Cell Disease
Interventions: Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support])., Self-monitoring of pain, stress, and opioid use + alerts/reminders.; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Interventions: Occlutech Atrial Flow Regulator Retrospective Data Collection; Device
Lead sponsor: Occlutech International AB; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 4 more

Conditions: Cystic Fibrosis
Interventions: Zinc acetate (20mg/d); Drug
Lead sponsor: Cystic Fibrosis Foundation; Other
Eligibility: 8 Years to 14 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 5 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autosomal Dominant Polycystic Kidney, ADPKD
Interventions: Tesevatinib, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: La Jolla, California • La Mesa, California • Los Angeles, California + 15 more

Conditions: Retinopathy of Prematurity
Interventions: Investigational ultracompact OCT and OCTA system, retinal photographs; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions: Losartan; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 5 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Lysosomal and Rare Disorders Research and Treatment Center, Inc.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Rockville, Maryland • Fairfax, Virginia

Conditions: Single-ventricle, Hepatic Congestion
Interventions: Fenestration status; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more

Conditions: Dermatitis, Atopic
Interventions: Triamcinolone 0.1%; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: tapinarof cream, 1%, Vehicle cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 53 more

Conditions: Lynch Syndrome
Interventions: Atorvastatin 20mg, Atorvastatin 20mg AND Aspirin 325 mg; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: Genetic Disease, Pediatrics, Predictive Model, Clinical Decision Support
Interventions: SIGHT Prompted Provider Message; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 1 Year to 20 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique; Genetic · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1975 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Friedreich Ataxia
Interventions: MR; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hereditary Ataxia
Interventions: Not listed
Lead sponsor: Office of Rare Diseases (ORD); NIH
Eligibility: 3 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Gaucher Disease
Interventions: Imiglucerase; Drug
Lead sponsor: University Research Foundation for Lysosomal Storage Diseases, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Beverly Hills, California • Coral Springs, Florida

Conditions: Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions: LPX-TI641, Placebo; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Fargo, North Dakota • Dallas, Texas

Search by objective public record fields.

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease

Occlutech AFR Fontan Study

Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)

Rod and Cone Mediated Function in Retinal Disease

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

Preventing Sickle Cell Kidney Disease

Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease

The Effect of Fontan Fenestration Closure on Hepatic Stiffness

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

Vitamin D3 in Patients With Sickle Cell Disease

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

TCA Cycle in the Dentate in Friedreich's Ataxia

Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)

Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis